Navigation Links
BioMedix™ Announces John Martin, MD, FACS, as Medical Director
Date:6/16/2011

SAINT PAUL, Minn., June 16, 2011 /PRNewswire/ -- BioMedix™, a health IT company focused on improving lives through integrated medical devices and software, announces the appointment of John Martin, MD, FACS, as Medical Director. A respected researcher and author, Dr. Martin is one of the only board certified Vascular Surgeons in the nation who is also the CEO of a major cardiology practice. Under Dr. Martin's leadership as Medical Director of Heart and Vascular Services and Director of Surgical Quality, Anne Arundel Medical Center (AAMC) has become a nationally recognized facility for the treatment of vascular disease. Dr. Martin has made a formidable contribution to our nation's preventive healthcare movement and will draw from his extensive expertise to provide leadership and guidance for BioMedix™ company initiatives.

"BioMedix™ continues to make a difference with its innovative products—BioMedix™ technology offers a platform for providers to collaborate to find and treat more patients with vascular disease," said Dr. Martin, "I am excited to join an organization that has long been dedicated to promoting early detection and prevention of cardiovascular events."

Joining the Anne Arundel Medical Center medical staff in 1999, Dr. Martin has served on various hospital committees, including the Strategic Planning Committee of the Board of Trustees. Dr. Martin has developed training, education and multiple research initiatives for AAMC, as well as a dedicated vascular patient unit. In 2000, he co-founded the Dare to C.A.R.E. Foundation, a nonprofit organization dedicated to informing the community about the threat and treatment of cardiovascular disease, providing free cardiovascular screenings to more than 30,000 individuals to date.

"The clinical experience and knowledge of vascular health that Dr. Martin brings to BioMedix™ will strengthen our continuing mission of advancing technology-enabled collaborative care," said John Romans, BioMedix™ President and CEO. "We are very pleased to have a medical professional of his caliber join our team."

Dr. Martin received his BS from the University of Texas at San Antonio. He then completed medical school, his residency in surgery and a fellowship in peripheral vascular surgery at the University of Texas Southwestern Medical Center in Dallas. He is board certified in vascular surgery. In his new role, Dr. Martin will be overseeing care improvement initiatives, research agendas and medical policy development for BioMedix™ medical devices and collaborative care platforms.

About BioMedix™

BioMedix™ is a leader in Health Information Technology (HIT) software, products and services that connect Podiatric Physicians, Primary Care Physicians, vascular labs, vascular specialists, hospitals and healthcare systems in a continuum of collaborative care. We provide the only integrated suite of hardware, software and online services designed to cost-effectively detect vascular disease. Our award-winning suite of medical devices, advanced practice management and Electronic Health Record (EHR) software and web-based solutions give providers a more complete view of patient care. For more information about BioMedix™ products, call 877-854-0014 or log on to www.BioMedix.com.


'/>"/>
SOURCE BioMedix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMedix™ Now Exclusive Industry Distributor of the APMA Coding Resource Center
2. International Drug & Explosives Detection Company IDenta Corp. Announces New Representative in Japan
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. American Medical Systems Announces Large-Scale, Physician-Led Registry of Penile Implants
5. Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent
6. Endologix Announces FDA Approval of AFX™ Endovascular AAA System
7. Fuisz Announces Issuance of Patent Concerning Product Supplier Database Sharing With an On-Line Vendor
8. Generex Announces Appointment of CEO for Post-Spinout Antigen Express
9. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
10. Masimo Announces Rainbow Agreement with Philips
11. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic ... Frederick area economy by obtaining investment capital for emerging technology companies. SCP ... that have already resulted in more than a million dollars of capital investment ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):